Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 20/20 | 0.90 |
| ▸ | BIRC2 | Q13490 | 13/20 | 0.90 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164801 | 1.00 | XIAP (0.90) | XIAPBIRC2BIRC3 | |
| SCHEMBL1163171 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL1164611 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL29441250 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL1273096 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL23350062 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL12932690 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL20372584 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL1273713 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 | |
| SCHEMBL1163843 | 0.95 | XIAP (1.00) | XIAPBIRC2BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | XIAP 2/4885BIRC2 3/4885BIRC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.